Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis

详细信息    查看全文

• 作者：Clara Matute-Blanch^a ; ^{clara.matute@vhir.org} ; Jordi Rí ; o^a ; Luisa M Villar^b ; Luciana Midaglia^a ; Sunny Malhotra^a ; José ; C Á ; lvarez-Cermeñ ; o^b ; Angela Vidal-Jordana^a ; Xavier Montalban^a ; Manuel Comabella^a ; ^{manuel.comabella@vhir.org}
• 关键词：CHI3L1 ; chitinase 3-like 1 ; MS ; multiple sclerosis ; RRMS ; relapsing-remitting multiple sclerosis ; CIS ; clinically isolated syndrome ; DMT ; disease modifying therapies ; IFNβ ; interferon-beta ; GA ; glatiramer acetate
• 刊名：Journal of Neuroimmunology
• 出版年：2017
• 出版时间：15 February 2017
• 年：2017
• 卷：303
• 期：Complete
• 页码：62-65
• 全文大小：319 K
• 卷排序：303

文摘

The prognostic involvement of CHI3L1 in clinically isolated syndromes is further studied. Serum CHI3L1 levels are increased by the effect of glatiramer acetate treatment. Non-responder patients to interferon-beta treatment have increased serum CHI3L1 levels. Results may suggest a role for CHI3L1 as an interferon-beta treatment response biomarker in RRMS patients.